Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Riskier stocks

<< Previous

Bullboard Posts

Next >>

Comment by Nicksonsnowboaron Nov 18, 2021 1:07pm

327 Views

Post# 34141608

RE:Riskier stocks

It's really a long term stock. The hype has been over for a while so who knows how far it will fall. Smart money vacated long ago . It's on a consistent downtrend because trial results are a long way off and no guarantees. Wait until something occurs . Right now people are just playing with it.

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market